The Impact of Radiotherapy on Immune Cells in Triple-Negative Breast Cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091445

Enrollment

Unknown

Registered

2024-10-29

Start date

2024-11-01

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Conventional Fractionated Radiotherapy (CFRT):None

Hypofractionated Radiotherapy (HFRT):None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.The patient voluntarily participates and signs a written informed consent form. 2.Pathologically or cytologically confirmed breast cancer. 3.Triple-negative breast cancer. 4.Stage T1-3N1-2M0. 5.Breast-conserving surgery or modified radical mastectomy. 6.Age >= 18 years. 7.ECOG performance status score of 0-1.

Exclusion criteria

Exclusion criteria: 1.Presence of other malignancies. 2.Coexisting severe systemic diseases. 3.Pregnant or breastfeeding women. 4.Previous receipt of systemic treatment related to breast cancer. 5.Active infections or uncontrolled inflammatory diseases. 6.Mental disorders or cognitive impairment. 7.History of severe allergic reactions.

Design outcomes

Primary

Measure	Time frame
lymphocyte percentage;	—

Secondary

Measure	Time frame
The total number of peripheral blood cells.;	—

Countries

China

Contacts

Public ContactBo Luo

Hubei Cancer Hospital

274890307@qq.com+86 180 6245 1356

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026